The renaissance of cardiac glycosides in heart failure: why, for whom and when

Key Result

Cardiac glycosides can reduce the risk of worsening heart failure events in selected patients with heart failure with reduced ejection fraction.

Key Points

• This research evaluates the role of cardiac glycosides in heart failure treatment and identifies suitable patient populations for their use.
• Analyzed data from two clinical trials focusing on patients with heart failure with reduced ejection fraction.
• Investigated the impact of cardiac glycosides on the risk of worsening heart failure events.
• Cardiac glycosides significantly reduced the risk of worsening heart failure events in targeted patients.
• The findings suggest a tailored role for cardiac glycosides without a need for a complete treatment paradigm shift.